EL7.AI
StocksMedium•17 November 2026•
4 min read

ME Therapeutics Reports Program Progress, Targets CAR Candidate Selection in Fourth Quarter

Key Facts

1ME Therapeutics expected to select its final CAR candidate and move to lipid nanoparticle formulation in the fourth quarter of 2026.
2On November 9, the company said it continues to advance its CAR program toward a first-in-human trial and is pursuing a potential Nasdaq listing.
3The agreed monthly fee with Orbiton was $2,800, for an initial term of 12 months.
4The investor relations adviser grant included options to purchase 125,000 shares at an exercise price of C$1.05 per share, vesting over 12 months.

ME Therapeutics said in a statement issued on November 9 that it continues to work to advance its CAR therapy program toward a first-in-human trial, while pursuing a potential Nasdaq listing. However, the scientific details corresponding to the update on CAR and mRNA candidates appeared in an earlier statement dated September 8, and no new update on them was confirmed on November 17. In the September statement, the company said it had developed two candidate constructs targeting CD19 and CD22, which were undergoing comparative preclinical testing. It also said at the time that it expected to select its final candidate and move to lipid nanoparticle formulation during the fourth quarter of 2026. The human trial and potential listing remain future steps the company has said it is pursuing.

The two constructs differ in how they combine CD19 and CD22 targeting, according to the company's description. The first uses a strategy to co-express two separate CARs, while the second combines the targets in a single tandem design. ME Therapeutics said the constructs were undergoing preclinical comparison, without announcing a final selection between them in the September statement. The fourth-quarter timeline cited by the company sets a stated timeframe for candidate selection and the move to lipid nanoparticle formulation. According to the company's plan, that formulation is the step before testing a CAR candidate in vivo.

In its therapeutic mRNA program, the company said a laboratory test of the new sequence showed a marked reduction in STING protein expression in a human liver cell line. It added that expression levels in non-liver cells showed no significant relative change. The next step, it said, is to formulate the therapeutic mRNA in lipid nanoparticles ahead of in vivo testing. The reported result remains tied to a laboratory test, while the September statement did not cite in vivo test results for this sequence. The update therefore covers two distinct development tracks: preclinical comparison of two CAR constructs and work to prepare an mRNA candidate for subsequent testing.

As for the listing effort, ME Therapeutics said in its September statement that it was working with its U.S. legal adviser and addressing the first round of comments on a draft F-1 registration statement. This describes a stage in the preparatory process for a potential Nasdaq listing; it does not mean the listing has taken place or that the company has confirmed a date. In January 2026, the company said it was working with Luckosky Brookman LLP to explore a potential listing on the Nasdaq Capital Market or the NYSE American, and that it had met with potential specialist investment banks for assistance. In November, the company linked its appointment of Orbiton Financial for investor relations services to efforts to raise market awareness, while continuing to develop the program toward a first-in-human trial. The CEO said: "We are now prioritizing market awareness while continuing to advance toward a first-in-human clinical trial."

Under its agreement with Orbiton, the company said the initial term is 12 months, for $2,800 per month plus pre-approved expenses. It said the agreement was signed on November 5 and took effect on November 3, with month-to-month continuation after the initial term and the option to terminate with 30 days' notice. It also said it granted its consulting head of investor relations options to purchase 125,000 common shares at an exercise price of C$1.05 per share, vesting monthly over 12 months. These arrangements relate to investor relations services, while in its November statement the company described a human CAR trial as a goal it continues to work toward. In its September statement, the company cautioned that test results might not be favorable or consistent with previous results, that its candidates might prove ineffective, and that there was no guarantee of obtaining a U.S. listing.